Monitoring the Response of Cyclin-Dependent Kinase 4/6 Inhibitors with Mean Corpuscular Volume

Monitoring the Response of Cyclin-Dependent Kinase 4/6 Inhibitors with Mean Corpuscular Volume

Background: Currently, the combination of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors and endocrine therapy is a first-line treatment for hormone-receptor-positive and HER2-negative metastatic breast cancer. This study aimed to assess the impact of changes in Mean Corpuscular Volume (MCV) on pre...

Full description

Bibliographic Details
Main Authors: Bediz Kurt İnci, Pınar Kubilay Tolunay, Şura Öztekin, Ergin Aydemir, İrem Öner, Öztürk Ateş, Cengiz Karaçin
Format: Article
Language:English
Published: MDPI AG 2024-09-01
Series:Current Oncology
Subjects:
mean corpuscular volume
CDK4/6
palbociclib
ribociclib
Online Access:https://www.mdpi.com/1718-7729/31/10/424

Internet

https://www.mdpi.com/1718-7729/31/10/424

Similar Items